We are delighted to announce that Sinokap has officially signed a partnership agreement with Mingma (Shanghai) Biotech Co., Ltd. As a leading IT service provider, Sinokap has been committed to delivering comprehensive IT support and consulting to businesses. We understand that a stable and efficient IT infrastructure is critical to sustained business growth.
Through this collaboration, we will closely align with Mingma’s evolving needs, providing tailored IT services and technical support to empower their technological innovation and business expansion.
Mingma Biotech, a subsidiary of WuXi AppTec, is headquartered in the Waigaoqiao Free Trade Zone in Shanghai, China. It is a pioneer in multi-omics research, specializing in genomics, transcriptomics, and proteomics. The company is dedicated to utilizing high-quality data and advanced applications to drive precision medicine and improve human health.
Mingma Biotech operates China’s first CLIA/CAP dual-certified laboratory (including Hong Kong, Macau, and Taiwan) and is also ISO15189-certified, ensuring compliance with global quality standards. As an integrated gene research and application platform, it offers both cloud-based and on-site services.
With a strong presence in Shanghai and surrounding regions, Mingma Biotech provides comprehensive solutions in multi-omics research and precision medicine to research institutions, pharmaceutical companies, and healthcare providers. The company supports disease mechanism research, drug development, and diagnostic reagent production, with notable contributions in rare genetic diseases, assisted reproduction, pathogen metagenomics, and oncology diagnostics
WuXi AppTec (Stock Codes: 603259.SH / 2359.HK) is a global leader in pharmaceutical and life sciences, offering end-to-end drug discovery, development, and manufacturing services. With operational bases in Asia, Europe, and North America, WuXi AppTec leverages its CRDMO (Contract Research, Development & Manufacturing Organization) and CTDMO (Contract Testing, Development & Manufacturing Organization) models to accelerate pharmaceutical R&D and provide breakthrough treatments to patients worldwide.
In 2023, WuXi AppTec was awarded an MSCI ESG (Environmental, Social, and Governance) AA rating for the third consecutive year. The company supports over 6,000 partners across 30+ countries, reinforcing its mission to bring innovative medicines and treatments to global patients.
Through this partnership, Sinokap will provide Mingma Biotech with specialized IT services, including:
1. On-Site IT Technical Support
Sinokap’s dedicated engineers will be stationed on-site to provide real-time assistance, backed by a 24/7 support team. This ensures seamless IT operations and immediate resolution of technical issues.
2. IT Security Consulting
Information security is a cornerstone of business success. Sinokap is committed to identifying potential security vulnerabilities and offering proactive solutions to strengthen cybersecurity and data protection.
3. Value-Added Services
To enhance client knowledge, Sinokap will publish monthly IT security insights through articles and videos, helping partners stay updated on the latest cybersecurity trends and best practices.
This partnership highlights Sinokap’s expertise in IT services and Mingma Biotech’s commitment to digital transformation. Looking ahead, we aim to deepen our collaboration, explore innovative IT solutions, and drive the integration of biotechnology and digital technology.
We look forward to a long-term, mutually beneficial partnership, creating greater value and advancing scientific research and healthcare solutions together.
Thank you to Mingma Biotech for their trust and partnership. Together, we are shaping the future of biotechnology and IT innovation!
Call Us, Write Us, Or Knock On Our Door. We are here to help. Thanks for contacting us!
如需任何协助,请随时联系Sinokap团队,我们始终致力于为您提供高效、专业的支持。
感谢您与我们联系!